Display Settings:

Format

Send to:

Choose Destination
    Gastrointest Endosc. 2009 Apr;69(4):777-83. Epub 2009 Jan 10.

    Low prevalence of submucosal invasive carcinoma at esophagectomy for high-grade dysplasia or intramucosal adenocarcinoma in Barrett's esophagus: a 20-year experience.

    Source

    Division of Gastroenterology and Hepatology, Brigham and Women's Hospital, and Harvard Medical School, Boston, Massachusetts 02215, USA.

    Abstract

    BACKGROUND:

    The rate of occult adenocarcinoma at esophagectomy in patients with Barrett's esophagus (BE) and high-grade dysplasia (HGD) has been reported to be approximately 40%. Recently, it has been suggested that this risk may be overestimated.

    OBJECTIVE:

    Our purpose was to determine the rate of submucosal invasive adenocarcinoma in patients undergoing esophagectomy for BE after biopsy diagnosis of HGD or intramucosal carcinoma (IMC). A secondary aim was to identify clinical risk factors for submucosal invasive adenocarcinoma in these patients.

    DESIGN:

    A retrospective study.

    SETTING:

    Tertiary referral center.

    PATIENTS:

    All patients with preoperative BE with HGD or IMC treated with esophagectomy over a 20 year period.

    INTERVENTIONS:

    Esophagectomy.

    MAIN OUTCOME MEASUREMENTS:

    Submucosal invasive adenocarcinoma at esophagectomy.

    RESULTS:

    Sixty patients were included (41 with preoperative HGD, 19 with preoperative IMC). The overall rate of submucosal invasive carcinoma was 6.7% (95% CI, 1.8%-16.2%) (n = 4), with a 5% rate of submucosal invasion in patients with preoperative HGD and 11% for patients with preoperative IMC. All 4 patients with submucosal invasion at esophagectomy had either nodular or ulcerated mucosa on preoperative endoscopy. The 1-year and 5-year all-cause risks of death for the entire cohort were 1.9% and 10.9%, respectively.

    LIMITATIONS:

    Retrospective study.

    CONCLUSIONS:

    The rate of submucosal invasive adenocarcinoma at esophagectomy in BE patients with HGD or IMC on biopsy is much lower than 40%. After adequate sampling and staging, patients with BE with HGD and IMC, especially those without endoscopically visible lesions, can potentially be treated by nonsurgical (local) therapies.

    PMID:
    19136106
    [PubMed - indexed for MEDLINE]

      Supplemental Content

      Click here to read

      Recent activity

      Your browsing activity is empty.

      Activity recording is turned off.

      Turn recording back on

      See more...
      Write to the Help Desk